Trial · NCT01839487
Adverse events504
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 504
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Anaemia | Blood and lymphatic system disorders | PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 63 | 160 | |
| other | Anaemia | Blood and lymphatic system disorders | AG: Nab-paclitaxel + Gemcitabine | 41 | 100 | |
| other | Leukopenia | Blood and lymphatic system disorders | PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 15 | 160 | |
| other | Leukopenia | Blood and lymphatic system disorders | AG: Nab-paclitaxel + Gemcitabine | 7 | 100 | |
| other | Lymphopenia | Blood and lymphatic system disorders | PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 8 | 160 | |
| other | Lymphopenia | Blood and lymphatic system disorders | AG: Nab-paclitaxel + Gemcitabine | 5 | 100 | |
| other | Neutropenia | Blood and lymphatic system disorders | PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 53 | 160 | |
| other | Neutropenia | Blood and lymphatic system disorders | AG: Nab-paclitaxel + Gemcitabine | 18 | 100 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 41 | 160 | |
| other | Thrombocytopenia | Blood and lymphatic system disorders | AG: Nab-paclitaxel + Gemcitabine | 17 | 100 | |
| other | Sinus tachycardia | Cardiac disorders | PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 6 | 160 | |
| other | Sinus tachycardia | Cardiac disorders | AG: Nab-paclitaxel + Gemcitabine | 5 | 100 | |
| other | Tachycardia | Cardiac disorders | PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 15 | 160 | |
| other | Tachycardia | Cardiac disorders | AG: Nab-paclitaxel + Gemcitabine | 7 | 100 | |
| other | Vision blurred | Eye disorders | PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 13 | 160 | |
| other | Vision blurred | Eye disorders | AG: Nab-paclitaxel + Gemcitabine | 5 | 100 | |
| other | Abdominal distension | Gastrointestinal disorders | PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 16 | 160 | |
| other | Abdominal distension | Gastrointestinal disorders | AG: Nab-paclitaxel + Gemcitabine | 9 | 100 | |
| other | Abdominal pain | Gastrointestinal disorders | PAG: PEGPH20 + Nab-paclitaxel + Gemcitabine | 51 | 160 | |
| other | Abdominal pain | Gastrointestinal disorders | AG: Nab-paclitaxel + Gemcitabine | 28 | 100 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01839487/events